E
Appili Therapeutics Inc. APLI.TO
TSX
Recommendation
Prev Close
Volume
--
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)
E
Sell 3/14/2023Downgrade
Appili Therapeutics Inc. (APLI.TO) was downgraded to E+ from D- on 03/14/2023.
D
Sell 2/15/2023Upgraded
Appili Therapeutics Inc. (APLI.TO) was upgraded to D- from E+ on 2/15/2023 due to an increase in the total return index.
E
Sell 2/8/2023Downgrade
Appili Therapeutics Inc. (APLI.TO) was downgraded to E+ from D- on 2/8/2023 due to a large decline in the solvency index, volatility index and valuation index. Debt to equity increased from -3.33 to -1.87.
D
Sell 8/15/2022Upgraded
Appili Therapeutics Inc. (APLI.TO) was upgraded to D- from E+ on 8/15/2022 due to a large increase in the growth index. Earnings per share increased from -$0.037 to -$0.02, and EBIT increased 16.17% from -$1.93M to -$1.62M.
E
Sell 7/29/2022Downgrade
Appili Therapeutics Inc. (APLI.TO) was downgraded to E+ from D- on 7/29/2022 due to a decline in the total return index and volatility index.
D
Sell 7/14/2022Upgraded
Appili Therapeutics Inc. (APLI.TO) was upgraded to D- from E+ on 7/14/2022 due to an increase in the valuation index and growth index. Operating cash flow increased 34.6% from -$4.66M to -$3.05M, and EBIT increased 24.74% from -$2.56M to -$1.93M.
E
Sell 12/15/2021Downgrade
Appili Therapeutics Inc. (APLI.TO) was downgraded to E+ from D- on 12/15/2021 due to a major decline in the solvency index, total return index and volatility index. The quick ratio declined from 2.28 to 0.76.
D
Sell 11/8/2021Downgrade
Appili Therapeutics Inc. (APLI.TO) was downgraded to D- from D on 11/08/2021.
D
Sell 9/29/2021Upgraded
Appili Therapeutics Inc. (APLI.TO) was upgraded to D from D- on 9/29/2021 due to an increase in the total return index.
D
Sell 8/27/2021Downgrade
Appili Therapeutics Inc. (APLI.TO) was downgraded to D- from D on 8/27/2021 due to a major decline in the growth index, solvency index and volatility index. Debt to equity increased from 0.08 to 0.17, operating cash flow declined 60.79% from -$3.43M to -$5.51M, and earnings per share declined from -$0.0629 to -$0.0955.
D
Sell 7/1/2020Upgraded
Appili Therapeutics Inc. (APLI.V) was upgraded to D from D- on 7/1/2020 due to a noticeable increase in the growth index, solvency index and total return index. The quick ratio increased from 2 to 7.88, debt to equity declined from 1.36 to 0.12, and earnings per share increased from -$0.0266 to -$0.0244.
D
Sell 3/2/2020Upgraded
Appili Therapeutics Inc. (APLI.V) was upgraded to D- from E on 3/2/2020 due to an increase in the volatility index, total return index and efficiency index.
E
Sell 12/2/2019Upgraded
Appili Therapeutics Inc. (APLI.V) was upgraded to E from E- on 12/2/2019 due to a large increase in the growth index and total return index. Earnings per share increased from -$0.0444 to -$0.0259, operating cash flow increased 32.34% from -$1.14M to -$770.5, and EBIT increased 27.4% from -$1.44M to -$1.05M.
E
Sell 9/18/2019None
Appili Therapeutics Inc. (APLI.TO) was downgraded to E- from U on 09/18/2019.
Weiss Ratings